Free Newsletter
Pharma offense is best reform defense
You know that pharma is joining the health-reform effort this time around, probably because company execs know they can't beat it completely. And you know that they're using that seat at the table to promote changes that they consider pharma-friendly. For lots more on drugmakers' offense-is-the-best-defense approach, check out the Wall Street Journal analysis. Report
More stories about healthcare reform
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: